MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

Search

Insulet Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

260.4 0.34

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

258.86

Max

260.77

Pagrindiniai rodikliai

By Trading Economics

Pajamos

23M

101M

Pardavimai

225M

598M

P/E

Sektoriaus vid.

41.275

57.333

Pelnas, tenkantis vienai akcijai

1.15

Pelno marža

16.854

Darbuotojai

3,900

EBITDA

25M

142M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+24.66% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-08

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2.7B

17B

Ankstesnė atidarymo kaina

260.06

Ankstesnė uždarymo kaina

260.4

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

Insulet Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-27 23:55; UTC

Rinkos pokalbiai

Oil Edges Higher Amid Hopes for Easing U.S.-China Trade Tensions -- Market Talk

2025-04-27 23:47; UTC

Rinkos pokalbiai

Gold Falls Amid Dollar Strength, Signs of Easing U.S.-China Trade Tensions -- Market Talk

2025-04-27 23:42; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About U.S.-China Tensions Ebb -- Market Talk

2025-04-27 23:12; UTC

Uždarbis

Sinopharm Group 1Q Rev CNY141.66B Vs. CNY147.27B >1099.HK

2025-04-27 23:12; UTC

Uždarbis

Sinopharm Group 1Q Net CNY1.46B Vs. Net CNY1.42B >1099.HK

2025-04-27 20:41; UTC

Uždarbis

Pharmaron Beijing 1Q Net CNY305.58M Vs. Net CNY230.56M >300759.SZ

2025-04-27 20:41; UTC

Uždarbis

Pharmaron Beijing: Higher Contributions From Laboratory Services Among Factors Supporting Results> 300759.SZ

2025-04-27 20:41; UTC

Uždarbis

Pharmaron Beijing 1Q Rev CNY3.10B Vs. CNY2.67B >300759.SZ

2025-04-27 18:41; UTC

Svarbiausios naujienos

Bessent Doesn't Know If Trump and Xi Have Talked on Trade -- Barrons.com

2025-04-27 11:00; UTC

Svarbiausios naujienos

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

2025-04-27 05:41; UTC

Uždarbis

China Everbright Bank 1Q Net CNY12.46B Vs. Net CNY12.43B >601818.SH

2025-04-27 05:41; UTC

Uždarbis

China Everbright Bank: Lower Net Interest Income Weighed on Operating Income>601818.SH

2025-04-27 05:41; UTC

Uždarbis

China Everbright Bank 1Q Operating Income CNY33.10B Vs. CNY34.49B>601818.SH

2025-04-27 05:41; UTC

Uždarbis

China Everbright Bank 1Q Impairment Loss on Credit Assets Was CNY8.49B; Down 15.6% on Year>601818.SH

2025-04-27 05:41; UTC

Uždarbis

China Everbright Bank 1Q Operating Expenses Was CNY9.15B; Down 3.2%>601818.SH

2025-04-27 05:41; UTC

Uždarbis

China Everbright Bank 1Q Net Interst Income Was CNY22.54B; Down 6.8% on Year>601818.SH

2025-04-27 05:34; UTC

Uždarbis

Chongqing Rural Commercial Bank: 1Q Results Supported by Higher Net Interest Income>3618.HK

2025-04-27 05:34; UTC

Uždarbis

Chongqing Rural Commercial Bank 1Q Operating Income CNY7.22B Vs. CNY7.13B>3618.HK

2025-04-27 05:34; UTC

Uždarbis

Chongqing Rural Commercial Bank 1Q Net CNY3.75B Vs. Net CNY3.52B >3618.HK

2025-04-27 05:29; UTC

Uždarbis

China Shenhua Energy: Results Weighed by Fall in Selling Prices of Coal >1088.HK

2025-04-27 05:29; UTC

Uždarbis

China Shenhua Energy 1Q Net CNY13.37B Vs. Net CNY17.76B >1088.HK

2025-04-27 05:29; UTC

Uždarbis

China Shenhua Energy 1Q Rev CNY69.59B Vs. CNY87.65B >1088.HK

2025-04-27 05:29; UTC

Uždarbis

China Shenhua Energy: Lower Revenue From Electricity Sales Also Hurt Results >1088.HK

2025-04-27 05:21; UTC

Uždarbis

CMOC Group 1Q Net CNY3.95B Vs. Net CNY2.07B >3993.HK

2025-04-27 05:21; UTC

Uždarbis

CMOC Group: Cost Cuts Also Among Factors that Boosted 1Q Net >3993.HK

2025-04-27 05:21; UTC

Uždarbis

CMOC Group 1Q Rev CNY46.01B Vs. CNY46.12B >3993.HK

2025-04-27 05:21; UTC

Uždarbis

CMOC Group: Increase in Prices of Copper, Cobalt Supported Results>3993.HK

2025-04-27 03:00; UTC

Svarbiausios naujienos

Chinese Manufacturers Are Scouring the World for New Buyers -- WSJ

2025-04-27 00:30; UTC

Svarbiausios naujienos

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ

2025-04-27 00:30; UTC

Svarbiausios naujienos

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ -2-

Akcijų palyginimas

Kainos pokytis

Insulet Corp Prognozė

Kainos tikslas

By TipRanks

24.66% į viršų

12 mėnesių prognozė

Vidutinis 325 USD  24.66%

Aukščiausias 355 USD

Žemiausias 293 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Insulet Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

14

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

246.24 / 261.62Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bullish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Insulet Corp

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.